- Home
- ICCC vs EQ Comparison
ICCC vs EQ Comparison
Compare ICCC & EQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ICCC
- EQ
- Stock Information
- Founded
- ICCC 1982
- EQ 2017
- Country
- ICCC United States
- EQ United States
- Employees
- ICCC N/A
- EQ N/A
- Industry
- ICCC Biotechnology: Pharmaceutical Preparations
- EQ Biotechnology: Pharmaceutical Preparations
- Sector
- ICCC Health Care
- EQ Health Care
- Exchange
- ICCC Nasdaq
- EQ Nasdaq
- Market Cap
- ICCC 28.0M
- EQ 24.8M
- IPO Year
- ICCC 1987
- EQ 2018
- Fundamental
- Price
- ICCC $4.71
- EQ $0.60
- Analyst Decision
- ICCC
- EQ Buy
- Analyst Count
- ICCC 0
- EQ 2
- Target Price
- ICCC N/A
- EQ $5.00
- AVG Volume (30 Days)
- ICCC 22.4K
- EQ 117.2K
- Earning Date
- ICCC 11-13-2024
- EQ 11-13-2024
- Dividend Yield
- ICCC N/A
- EQ N/A
- EPS Growth
- ICCC N/A
- EQ N/A
- EPS
- ICCC N/A
- EQ N/A
- Revenue
- ICCC $23,838,001.00
- EQ $45,914,000.00
- Revenue This Year
- ICCC N/A
- EQ $4.76
- Revenue Next Year
- ICCC N/A
- EQ N/A
- P/E Ratio
- ICCC N/A
- EQ N/A
- Revenue Growth
- ICCC 46.37
- EQ 7.70
- 52 Week Low
- ICCC $3.34
- EQ $0.56
- 52 Week High
- ICCC $5.82
- EQ $3.25
- Technical
- Relative Strength Index (RSI)
- ICCC 56.95
- EQ 34.19
- Support Level
- ICCC $4.38
- EQ $0.56
- Resistance Level
- ICCC $5.23
- EQ $0.67
- Average True Range (ATR)
- ICCC 0.47
- EQ 0.05
- MACD
- ICCC -0.04
- EQ -0.00
- Stochastic Oscillator
- ICCC 22.92
- EQ 20.00
About ICCC ImmuCell Corporation
ImmuCell Corp is engaged in the healthcare sector. The company operates in the development, acquisition, manufacture, and sale of products that improve the health and productivity of cows for the dairy and beef industries. The company operates in two business segment. The Scours segment is dedicated to manufacturing and selling First Defense, a product used to prevent scours in newborn calves, which is regulated by the United States Department of Agriculture (USDA). The Mastitis segment is focused on developing and commercializing Re-Tain, a product to treat subclinical mastitis in lactating dairy cows, which is regulated by the United States Food and Drug Administration (FDA). The company generates the majority of its revenue from the Scours segment.
About EQ Equillium Inc.
Equillium Inc is a biotechnology developing therapies to treat severe autoimmune and inflammatory disorders. Its pipeline includes itolizumab, a first-in-class antibody targeting the CD6-ALCAM pathway which plays a key role in the modulation of effector T cells - currently in a Ph 3 study for patients with acute graft-versus-host disease and a Ph 1b study for patients with lupus nephritis. EQ101, a first-in-class cytokine inhibitor that selectively targets IL-2, IL-9, and IL-15 is Ph2-ready and expected to begin enrolling patients in an alopecia areata study in 2H 2022. EQ102, a cytokine inhibitor that selectively targets IL-15 and IL-21, is ready for clinical development and expected to begin enrolling patients in a Ph 1study including patients with celiac disease.